Swiss pharma giant Roche has given itself a pricey holiday gift and deepened its oncology product portfolio with its $1.7 billion acquisition of immuno-oncology business Ignyta. Based in San Diego, the company tests, identifies, and treat patients with cancers that come with rare mutations.
{iframe}https://medcitynews.com/2017/12/roches-1-7b-precision-medicine-acquisition-ignyta-targets-cancers-rare-mutations/?_hsenc=p2ANqtz–G2lCYiTMzJgq43_xh_3geamW4xcOZAyZiH-c9NgYev6hLIKhcCqzzNgQH7VE9TeGsNCmMJJwIFmOoNl0d9oYLxJ6FgQ&_hsmi=59618936{/iframe}